ClinicalTrials.gg
Active, not recruitingNCT03981003NeurofilMSUpdated Oct 21, 2026

Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis

An observational study in Multiple Sclerosis, sponsored by Centre Hospitalier Universitaire de Nīmes. Active, not recruiting at 28 sites in 2 countries. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational

How we know

Updated Oct 21, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,150
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes — 1 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · Centre Hospitalier Universitaire de Nīmes.

Started
2019
with 2 others
Observational
7 of 13
none open now
Registered
7th of 13
by date

Among the 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes, this one is one of 3 that started in 2019, is one of 7 observational ones, and was the 7th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

1 of the 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes, or all of them as a file.
02

Study summary

The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease.

In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Neurofilament-light chain
  • Glial fibrillary Acidic Protein (GFAP)
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population is composed of consecutive patients over 15 years of age, of both sexes, recruited during consultations for a CIS, RRMS or progressive MS at the Neurology department of 30 OFSEP centres and of Nîmes and Nantes University Hospitals. The patients recruited will have an EDSS score comprised between 0 - 7.0.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has been correctly informed.
  • The patient must have given their informed and signed consent.
  • The patient must be insured or beneficiary of a health insurance plan.
  • The patient is at least (≥)15 years old.
  • The patient has MS according to diagnosis criteria (Thompson et al. 2017) and:

    • Participates to the OFSEP-HD cohort (ancillary study);
    • Has a Expanded Disability Status Scale score comprised between 0 - 7.0;
    • With or without Disease Modifying Drug;
    • For Work Package 3: patients enrolled in any OFSEP-HD centre that meet landmark criteria for an active MS (relapse, or Expanded Disability Status Scale progression, or active MRI) during follow-up;
    • For Work Package 4: patients with a stable disease enrolled in OFSEP-HD study in Nîmes or Nantes University Hospitals.

Exclusion criteria

Exclusion Criteria:

  • Within the past three months, the patient has participated in another interventional study that may interfere with the results or conclusions of this study.
  • The patient is in an exclusion period determined by a previous study.
  • The patient is under judicial protection.
  • The patient refuses to sign the consent.
  • It is impossible to correctly inform the patient (inability to understand the study, language problem).
  • The patient is pregnant or breast-feeding.
  • The patient is under 15 years old.
  • Inability to answer questionnaires.
  • Clinically isolated syndrome (CIS) that does not meet the criteria of MS.
  • Radiologically isolated syndrome (RIS).
  • Patient with Neuromyelitis optica spectrum disorder.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • MS Patients

    Diagnostic Test: Blood sample

Interventions

  • Diagnostic testBlood sample

    2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels

06

What researchers measure

Primary outcomes

  1. Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  2. GFAP level in patients with evolving disease compared to those with stable disease

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  3. Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  4. GFAP level in patients with evolving disease compared to those with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  5. Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 12 months

  6. GFAP level in patients with evolving disease compared to those with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 12 months

  7. Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  8. GFAP level in patients with evolving disease compared to those with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  9. Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  10. GFAP level in patients with evolving disease compared to those with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 3 years

  11. GFAP level in patients with evolving disease compared to those with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 4 years

  12. GFAP level in patients with evolving disease compared to those with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 5 years

  13. GFAP level in patients with evolving disease compared to those with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 6 years

Secondary outcomes

  1. Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  2. GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  3. Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  4. GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  5. Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  6. Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.

    pg/mL; measured by digital ELISA

    Time frame: 3 year

  7. Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.

    pg/mL; measured by digital ELISA

    Time frame: 4 year

  8. Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.

    pg/mL; measured by digital ELISA

    Time frame: 5 year

  9. Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.

    pg/mL; measured by digital ELISA

    Time frame: 6 year

  10. GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  11. Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  12. GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  13. Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  14. GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  15. Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  16. GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  17. Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  18. GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  19. Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  20. GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  21. Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  22. GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  23. Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  24. GFAP level in patients with relapse compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  25. Serum Neurofilament Light Chain level in patients with relapse compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  26. GFAP level in patients with relapse compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  27. Serum Neurofilament Light Chain level in patients with relapse compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  28. GFAP level in patients with relapse compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  29. Serum Neurofilament Light Chain level in patients with relapse compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  30. GFAP level in patients with relapse compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  31. Serum Neurofilament Light Chain level in patients with relapse compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  32. GFAP level in patients with relapse compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  33. Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  34. GFAP level in patients with isolated MRI activity compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  35. Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  36. GFAP level in patients with isolated MRI activity compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  37. Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  38. Serum GFAP level in patients with isolated MRI activity compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  39. Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  40. Serum GFAP level in patients with isolated MRI activity compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  41. Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  42. Serum GFAP level in patients with isolated MRI activity compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  43. Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  44. Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  45. Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  46. Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  47. Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  48. Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  49. Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  50. Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  51. Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 2 year

  52. Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 2 year

  53. Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  54. Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  55. Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  56. Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  57. Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  58. Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  59. Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  60. Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  61. Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  62. Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  63. Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  64. Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  65. Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  66. Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  67. Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  68. Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  69. Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  70. Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  71. Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  72. Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  73. Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  74. Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  75. Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  76. Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  77. Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  78. Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  79. Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  80. Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  81. Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  82. Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  83. Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  84. Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  85. Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  86. Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  87. Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  88. Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  89. Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  90. Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  91. Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  92. Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  93. Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  94. Serum GFAP level in patients with disease activity (relapse or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  95. Serum Neurofilament Light Chain level in patients with disease activity (relapse, or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  96. Serum GFAP level in patients with disease activity (relapse, or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  97. Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  98. Serum GFAP level in patients with disease activity (relapse or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  99. Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  100. Serum GFAP level in patients with disease activity (relapse or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  101. Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  102. Serum GFAP level in patients with disease activity (relapse or MRI activity)

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  103. Serum Neurofilament Light Chain level in patients with relapses

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  104. Serum GFAP level in patients with relapses

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  105. Serum Neurofilament Light Chain level in patients with relapses

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  106. Serum GFAP level in patients with relapses

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  107. Serum Neurofilament Light Chain level in patients with relapses

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  108. Serum GFAP level in patients with relapses

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  109. Serum Neurofilament Light Chain level in patients with relapses

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  110. Serum GFAP level in patients with relapses

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  111. Serum Neurofilament Light Chain level in patients with relapses

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  112. Serum GFAP level in patients with relapses

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  113. Serum Neurofilament Light Chain level in patients with MRI activity

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  114. Serum GFAP level in patients with MRI activity

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  115. Serum Neurofilament Light Chain level in patients with MRI activity

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  116. Serum GFAP level in patients with MRI activity

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  117. Serum Neurofilament Light Chain level in patients with MRI activity

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  118. Serum GFAP level in patients with MRI activity

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  119. Serum Neurofilament Light Chain level in patients with MRI activity

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  120. Serum GFAP level in patients with MRI activity

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  121. Serum Neurofilament Light Chain level in patients with MRI activity

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  122. Serum GFAP level in patients with MRI activity

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  123. Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  124. Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  125. Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  126. Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  127. Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  128. Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  129. Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  130. Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  131. Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  132. Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  133. Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  134. Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  135. Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  136. Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 6 months

  137. Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  138. Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 1 year

  139. Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  140. Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 18 months

  141. Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  142. Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  143. Level of disability

    Expanded Disability Status Scale (EDSS); scale 1= no disability to 10 = death from multiple sclerosis

    Time frame: Inclusion

  144. Level of disability

    Expanded Disability Status Scale (EDSS); scale 1= no disability to 10 = death from multiple sclerosis

    Time frame: Relapse (measured up to 2 years)

  145. Severity of multiple sclerosis

    Multiple Sclerosis Functional Composite

    Time frame: EDSS progression (measured up to 2 years)

  146. Severity of multiple sclerosis

    Multiple Sclerosis Functional Composite

    Time frame: Active MRI (measured up to 2 years)

  147. Generic health status

    EuroQol 5 dimension questionnaire (EQ-5D)

    Time frame: Inclusion

  148. Generic health status

    EuroQol 5 dimension questionnaire (EQ-5D)

    Time frame: Relapse (measured up to 2 years)

  149. Generic health status

    EuroQol 5 dimension questionnaire (EQ-5D)

    Time frame: EDSS progression (measured up to 2 years)

  150. Generic health status

    EuroQol 5 dimension questionnaire (EQ-5D)

    Time frame: active MRI (measured up to 2 years)

  151. Use of Disease Modifying Drugs

    Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)

    Time frame: Inclusion

  152. Use of Disease Modifying Drugs

    Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)

    Time frame: 6 monrths

  153. Use of Disease Modifying Drugs

    Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)

    Time frame: 1 year

  154. Use of Disease Modifying Drugs

    Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)

    Time frame: 18 months

  155. Use of Disease Modifying Drugs

    Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)

    Time frame: 2 years

  156. Serum Neurofilament Light Chain in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  157. Serum GFAP in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  158. Serum Neurofilament Light Chain in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients

    pg/mL; measured by digital ELISA

    Time frame: Month 6

  159. Serum GFAP in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients

    pg/mL; measured by digital ELISA

    Time frame: Month 6

  160. Serum Neurofilament Light Chain in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  161. Serum GFAP in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion

    pg/mL; measured by digital ELISA

    Time frame: Inclusion

  162. Serum Neurofilament Light Chain in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion

    pg/mL; measured by digital ELISA

    Time frame: Month 6

  163. Serum GFAP in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion

    pg/mL; measured by digital ELISA

    Time frame: Month 6

  164. Create biobank

    Blood samples

    Time frame: Inclusion

  165. Create biobank

    Blood samples

    Time frame: 6 months

  166. Create biobank

    Blood samples

    Time frame: 1 year

  167. Create biobank

    Blood samples

    Time frame: 18 months

  168. Create biobank

    Blood samples

    Time frame: 2 years

07

Study locations

28 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for Jun 2027, 97 months after the start.

Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 97 months is above that.

Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Jun 2028 → Jun 2027 and completion Jun 2028 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2019
First posted
Jun 10, 2019
StartActual
May 22, 2019
Primary completionEst.
Jun 2027was Jun 2028
CompletionEst.
Jun 2027was Jun 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 21, 2026
Sites
1 site added, 1 site removed
Show site
  • CHU de Saint Etienne · Saint-Etienne, France
Show 1 removed
  • CHU de Saint Etienne · Saint-Étienne, France
Oct 21, 2026
Primary completion
Jun 2028→Jun 2027
Oct 21, 2026
Study completion
Jun 2028→Jun 2027
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • CHU de Saint Etienne · Saint-Etienne, France
    Show 1 removed
    • CHU de Saint Etienne · Saint-Étienne, France
    Primary completion Jun 2028→Jun 2027
    Study completion Jun 2028→Jun 2027
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03981003
Responsible party
Sponsor
First posted
Jun 10, 2019
Start date
May 22, 2019
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Eric Thouvenot
principal investigator · CHU Nimes

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion